Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) EBT Margin (2020 - 2025)

Historic EBT Margin for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to 1422.14%.

  • TScan Therapeutics' EBT Margin rose 14269500.0% to 1422.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 1680.02%, marking a year-over-year decrease of 4911400.0%. This contributed to the annual value of 4488.96% for FY2024, which is 40651000.0% down from last year.
  • Latest data reveals that TScan Therapeutics reported EBT Margin of 1422.14% as of Q3 2025, which was up 14269500.0% from 1201.3% recorded in Q2 2025.
  • TScan Therapeutics' 5-year EBT Margin high stood at 271.99% for Q4 2023, and its period low was 5906.9% during Q2 2024.
  • Its 5-year average for EBT Margin is 1548.87%, with a median of 604.94% in 2022.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -51430800bps in 2024, then soared by 47056000bps in 2025.
  • Quarter analysis of 5 years shows TScan Therapeutics' EBT Margin stood at 497.55% in 2021, then fell by -22bps to 604.94% in 2022, then soared by 55bps to 271.99% in 2023, then crashed by -1820bps to 5220.9% in 2024, then surged by 73bps to 1422.14% in 2025.
  • Its last three reported values are 1422.14% in Q3 2025, 1201.3% for Q2 2025, and 1571.95% during Q1 2025.